Kadima Pharmaceuticals, Inc

ACADIA Pharmaceuticals is a biopharmaceutical company utilizing technology to fuel drug discovery and clinical development of treatments for central nervous system disorders. It has five drug programs in clinical and pre-clinical development directed at large unmet medical needs and major commercial markets. ACADIA s three Phase II-stage clinical programs are ACP-103 for treatment-induced dysfunction in Parkinson's disease, ACP-103 as an adjunctive therapy for schizophrenia and ACP-104 for treatment of schizophrenia. The company also has clinical and pre-clinical development programs in the areas of neuropathic pain and glaucoma in collaboration with Allergan. ACADIA maintains headquarters and biology research facilities in San Diego and a chemistry research facility in Malmo, Sweden. It trades on NASDAQ under the symbol ACAD.

Travere Therapeutics, Inc. is a San Diego-based biopharmaceutical company focused on developing life-changing therapies for individuals living with rare diseases, particularly in the fields of rare kidney and metabolic disorders. The company is dedicated to advancing science that has the potential to set new standards of care and improve patients' lives. With a strong commitment to patient advocacy, Travere engages with the community through initiatives like the "Play It Forward" campaign, aimed at raising awareness for conditions such as Focal Segmental Glomerulosclerosis (FSGS) and IgA Nephropathy (IgAN). Their mission is driven by the needs of patients, caregivers, and advocates, emphasizing resilience and support within the rare disease community. Generated from the website

Orphagen Pharmaceuticals, located in San Diego, is a leading biopharmaceutical company specializing in innovative drug discovery and development. Their state-of-the-art facilities on Sorrento Valley Rd. are dedicated to advancing cutting-edge research and delivering groundbreaking therapies to improve patient outcomes. Generated from their website's infomation